<DOC>
	<DOCNO>NCT02606383</DOCNO>
	<brief_summary>This non-inferiority , Phase III , open-label , randomize , parallel trial evaluate new intervention Dapaconazole cream 2 % versus Ketoconazole cream 2 % patient Tinea pedis . Sample size 140 participant ( 70 per treatment group ) , male female , age 16 60 years-old . Primary objective evaluate non-inferiority Dapaconazole cream 2 % compare Ketoconazole cream 2 % Tinea pedis treatment . Secondary objective evaluate safety tolerability Dapaconazole cream 2 % multiple administration . Participants receive either new intervention active control 14 consecutive day , follow 2 follow-up visit . Primary efficacy endpoint clinical mycological lesion cure , secondary efficacy endpoint time ( day ) clinical diagnosis lesion cure . Additionally , safety assess adverse event occurrence laboratory exams evaluation .</brief_summary>
	<brief_title>Non-inferiority Phase III Trial Comparing Dapaconazole Cream 2 % With Ketoconazole Cream 2 % Patients With Tinea Pedis</brief_title>
	<detailed_description />
	<mesh_term>Tinea</mesh_term>
	<mesh_term>Tinea Pedis</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>Male female study participant , age 16 60 yearsold . Patients age 16 18 yearsold provide additional Assent Form enrollment trial ; Presence skin lesion characteristic Tinea pedis , diagnosis confirm direct mycological exam ; Absence previous antifungic treatment lesion study ; Absence significant disease , physician 's discretion , could impact subject 's participation trial , accord protocol requirement , study evaluation : medical history , blood pressure heart rate measurement , physical examination screen laboratory test ; Ability understand nature objective trial , include risk adverse event ; willingness cooperate researcher proceed accord study requirement , shall confirm Informed Consent Form signature . Known hypersensitivity ketoconazole chemically related compound ; history serious adverse reaction ; Screening laboratory test result show clinically relevant deviation , researcher discretion , prevent subject participate trial due possible risk ; Drugs addiction , include alcohol ; Use previous treatment lesion study , accord principal investigator best judgement , might interfere study objective ; Treatment , within 3 month trial , drug know wellestablished toxic potential major organ ; Participation experimental research administration experimental drug within 6 month trial ; Pregnancy , labor miscarriage 12 week study treatment ; Any condition , accord investigator 's best judgement , prevents subject participate trial .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>